Standard Chem & Pharm CO., LTD. (1720.TW)
TWD 57.2
(-0.35%)
TWD 57.2
(-0.35%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 1.25 Billion TWD | -12.32% |
| 2022 | 1.43 Billion TWD | 40.57% |
| 2021 | 1.02 Billion TWD | 32.02% |
| 2020 | 774.06 Million TWD | 31.14% |
| 2019 | 590.24 Million TWD | 48.01% |
| 2018 | 398.78 Million TWD | -26.35% |
| 2017 | 541.47 Million TWD | 29.5% |
| 2016 | 418.13 Million TWD | 9.04% |
| 2015 | 383.48 Million TWD | 1.63% |
| 2014 | 377.32 Million TWD | 42.28% |
| 2013 | 265.19 Million TWD | 23.59% |
| 2012 | 214.57 Million TWD | 3.43% |
| 2011 | 207.45 Million TWD | -35.84% |
| 2010 | 323.34 Million TWD | 6.83% |
| 2009 | 302.66 Million TWD | -8.98% |
| 2008 | 332.52 Million TWD | 7.57% |
| 2007 | 309.13 Million TWD | -13.43% |
| 2006 | 357.09 Million TWD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 437.05 Million TWD | 42.32% |
| 2024 Q2 | 373.13 Million TWD | -14.63% |
| 2023 Q4 | 307.08 Million TWD | -25.32% |
| 2023 Q2 | 414.21 Million TWD | 12.59% |
| 2023 Q1 | 367.9 Million TWD | 28.16% |
| 2023 Q3 | 411.19 Million TWD | -0.73% |
| 2023 FY | 1.25 Billion TWD | -12.32% |
| 2022 Q4 | 287.06 Million TWD | -37.3% |
| 2022 FY | 1.43 Billion TWD | 40.57% |
| 2022 Q3 | 457.8 Million TWD | 14.18% |
| 2022 Q2 | 400.93 Million TWD | 37.92% |
| 2022 Q1 | 290.7 Million TWD | 26.35% |
| 2021 Q3 | 229.47 Million TWD | 13.53% |
| 2021 Q4 | 230.08 Million TWD | 0.27% |
| 2021 Q1 | 203.8 Million TWD | 11.98% |
| 2021 FY | 1.02 Billion TWD | 32.02% |
| 2021 Q2 | 202.13 Million TWD | -0.82% |
| 2020 Q1 | 152.71 Million TWD | -4.73% |
| 2020 Q4 | 182 Million TWD | 12.08% |
| 2020 Q3 | 162.38 Million TWD | -20.03% |
| 2020 FY | 774.06 Million TWD | 31.14% |
| 2020 Q2 | 203.05 Million TWD | 32.97% |
| 2019 Q2 | 150.81 Million TWD | 230.84% |
| 2019 FY | 590.24 Million TWD | 48.01% |
| 2019 Q4 | 160.28 Million TWD | 4.68% |
| 2019 Q3 | 153.11 Million TWD | 1.53% |
| 2019 Q1 | 45.58 Million TWD | -61.9% |
| 2018 FY | 398.78 Million TWD | -26.35% |
| 2018 Q4 | 119.64 Million TWD | -1.63% |
| 2018 Q3 | 121.61 Million TWD | 28.85% |
| 2018 Q2 | 94.38 Million TWD | 49.51% |
| 2018 Q1 | 63.13 Million TWD | -35.69% |
| 2017 FY | 541.47 Million TWD | 29.5% |
| 2017 Q1 | 120.24 Million TWD | 18.17% |
| 2017 Q4 | 98.16 Million TWD | -47.36% |
| 2017 Q3 | 186.5 Million TWD | 36.57% |
| 2017 Q2 | 136.56 Million TWD | 13.58% |
| 2016 Q2 | 105.99 Million TWD | 10.27% |
| 2016 FY | 418.13 Million TWD | 9.04% |
| 2016 Q1 | 96.12 Million TWD | 30.42% |
| 2016 Q4 | 101.75 Million TWD | -10.94% |
| 2016 Q3 | 114.25 Million TWD | 7.79% |
| 2015 FY | 383.48 Million TWD | 1.63% |
| 2015 Q4 | 73.7 Million TWD | -20.25% |
| 2015 Q3 | 92.42 Million TWD | -9.04% |
| 2015 Q2 | 101.61 Million TWD | -12.21% |
| 2015 Q1 | 115.74 Million TWD | 63.0% |
| 2014 Q4 | 71 Million TWD | -19.03% |
| 2014 FY | 377.32 Million TWD | 42.28% |
| 2014 Q1 | 100.92 Million TWD | 296.4% |
| 2014 Q2 | 117.7 Million TWD | 16.63% |
| 2014 Q3 | 87.69 Million TWD | -25.5% |
| 2013 Q4 | 25.46 Million TWD | -53.0% |
| 2013 FY | 265.19 Million TWD | 23.59% |
| 2013 Q3 | 54.17 Million TWD | -13.65% |
| 2013 Q1 | 122.81 Million TWD | 82.29% |
| 2013 Q2 | 62.74 Million TWD | -48.91% |
| 2012 Q3 | 51.54 Million TWD | 5.81% |
| 2012 Q4 | 67.37 Million TWD | 30.7% |
| 2012 Q2 | 48.71 Million TWD | -0.68% |
| 2012 FY | 214.57 Million TWD | 3.43% |
| 2012 Q1 | 49.04 Million TWD | 2.37% |
| 2011 Q3 | 46.65 Million TWD | -23.06% |
| 2011 Q4 | 47.91 Million TWD | 2.69% |
| 2011 FY | 207.45 Million TWD | -35.84% |
| 2011 Q1 | 52.23 Million TWD | -33.22% |
| 2011 Q2 | 60.64 Million TWD | 16.09% |
| 2010 Q1 | 76.15 Million TWD | 0.0% |
| 2010 FY | 323.34 Million TWD | 6.83% |
| 2010 Q4 | 78.22 Million TWD | -0.83% |
| 2010 Q3 | 78.88 Million TWD | -12.43% |
| 2010 Q2 | 90.07 Million TWD | 18.29% |
| 2009 FY | 302.66 Million TWD | -8.98% |
| 2008 FY | 332.52 Million TWD | 7.57% |
| 2007 FY | 309.13 Million TWD | -13.43% |
| 2006 FY | 357.09 Million TWD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Grape King Bio Ltd | 2.49 Billion TWD | 49.551% |
| Maywufa Company Ltd. | 211.01 Million TWD | -496.89% |
| ScinoPharm Taiwan, Ltd. | 314.49 Million TWD | -300.505% |
| Lotus Pharmaceutical Co., Ltd. | 4.9 Billion TWD | 74.31% |
| LIWANLI Innovation Co., Ltd. | - TWD | -Infinity% |
| YungShin Global Holding Corporation | 929.61 Million TWD | -35.492% |
| PhytoHealth Corporation | -121.67 Million TWD | 1135.16% |
| SCI Pharmtech, Inc. | 160.3 Million TWD | -685.747% |
| Formosa Laboratories, Inc. | 674.97 Million TWD | -86.607% |
| PharmaEssentia Corporation | - TWD | -Infinity% |
| Bora Pharmaceuticals Co., LTD. | 5.24 Billion TWD | 76.005% |